Cerus Corporation (CERS) Initiates Patient Enrollment in European Phase III Clinical Trials for INTERCEPT Red Blood Cells for Acute and Chronic Anemia
6/11/2013 9:53:11 AM
More...
|
First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus Corporation (CERS)
5/28/2013 9:43:35 AM
More...
|
Cerus Corporation (CERS) Reports First Quarter 2013 Results
5/1/2013 7:22:46 AM
More...
|
Cerus Corporation (CERS) Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets
4/24/2013 11:40:36 AM
More...
|
Cerus Corporation (CERS) to Release First Quarter 2013 Results on April 30, 2013
4/17/2013 7:31:49 AM
More...
|
Cerus Corporation (CERS) Signs Intercept Ltd. Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria
3/15/2013 10:10:32 AM
More...
|
Cerus Corporation (CERS) Reports Fourth Quarter and Year-End 2012 Results
3/1/2013 7:09:53 AM
More...
|
Cerus Corporation (CERS) to Present at the Cowen and Company 33rd Annual Health Care Conference on March 6, 2013
2/27/2013 6:49:39 AM
More...
|
Cerus Corporation (CERS) to Release Fourth Quarter and Year-End 2012 Results on February 28, 2013
2/14/2013 7:07:27 AM
More...
|
Cerus Corporation (CERS) Announces FDA Agreement on Modular Premarket Approval Application (PMA) Submission Process for INTERCEPT Plasma
12/13/2012 10:20:24 AM
More...
|
|